Development and registration of recombinant veterinary vaccines The example of the canarypox vector platform
The canarypox vaccine vector (ALVAC) technology has been used to develop and license several vaccines for companion animals and horses in the European Union and USA. ALVAC is a ubiquitous vector with high biosafety since it is non-replicative in mammalians, is genetically and physically stable, and...
Gespeichert in:
| Veröffentlicht in: | Vaccine 2007-07, Vol.25 (30), p.5606-5612 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 5612 |
|---|---|
| container_issue | 30 |
| container_start_page | 5606 |
| container_title | Vaccine |
| container_volume | 25 |
| creator | POULET, Hervé MINKE, Jules PARDO, Maria Camila JUILLARD, Véronique NORDGREN, Bob AUDONNET, Jean-Christophe |
| description | The canarypox vaccine vector (ALVAC) technology has been used to develop and license several vaccines for companion animals and horses in the European Union and USA. ALVAC is a ubiquitous vector with high biosafety since it is non-replicative in mammalians, is genetically and physically stable, and able to induce both humoral and cell-mediated immune responses against the expressed transgene product. Specific rules apply for the development and registration of recombinant vector vaccines. The biology of the vector as well as the recombinant virus must be thoroughly documented to allow the risk assessment of its use in the target species. In particular, its safety for the host and the environment must be extensively demonstrated before field trials can be authorized. |
| doi_str_mv | 10.1016/j.vaccine.2006.11.066 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_70726131</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3420807511</sourcerecordid><originalsourceid>FETCH-LOGICAL-p298t-765295aaa3bbf7445e83cbdb14384a260cb5b13a2eee47d5a41fd12aa7248cc93</originalsourceid><addsrcrecordid>eNqF0M-L1TAQB_Agivt29U9QCqK31snv9Ci7ugoLXlbwVqbpVPtom5rkPdb_3jx8InjxlBnmkwn5MvaCQ8OBm7f75ojeTys1AsA0nDdgzCO2487KWmjuHrMdCKNqxeHrBbtMaQ8AWvL2KbvgVghrWtix-YaONIdtoTVXuA5VpG9TyhHzFNYqjKX3YemnFcv8SJliKePP6vx4qu6_U0UPuGwznXgurccT2cJDueBziNU2Yx5DXJ6xJyPOiZ6fzyv25cP7--uP9d3n20_X7-7qTbQu19Zo0WpElH0_WqU0Oen7oedKOoXCgO91zyUKIlJ20Kj4OHCBaIVy3rfyir35vXeL4ceBUu6WKXmaZ1wpHFJnwQrDJf8vFGChBCULfPUP3IdDXMsnOq51Cy2AO617eVaHfqGh2-K0lCS6P3EX8PoMMHmcx4irn9Jf51rttDPyFz77kpU</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1559090081</pqid></control><display><type>article</type><title>Development and registration of recombinant veterinary vaccines The example of the canarypox vector platform</title><source>Elsevier ScienceDirect Journals Complete - AutoHoldings</source><source>MEDLINE</source><source>ProQuest Central UK/Ireland</source><creator>POULET, Hervé ; MINKE, Jules ; PARDO, Maria Camila ; JUILLARD, Véronique ; NORDGREN, Bob ; AUDONNET, Jean-Christophe</creator><creatorcontrib>POULET, Hervé ; MINKE, Jules ; PARDO, Maria Camila ; JUILLARD, Véronique ; NORDGREN, Bob ; AUDONNET, Jean-Christophe</creatorcontrib><description>The canarypox vaccine vector (ALVAC) technology has been used to develop and license several vaccines for companion animals and horses in the European Union and USA. ALVAC is a ubiquitous vector with high biosafety since it is non-replicative in mammalians, is genetically and physically stable, and able to induce both humoral and cell-mediated immune responses against the expressed transgene product. Specific rules apply for the development and registration of recombinant vector vaccines. The biology of the vector as well as the recombinant virus must be thoroughly documented to allow the risk assessment of its use in the target species. In particular, its safety for the host and the environment must be extensively demonstrated before field trials can be authorized.</description><identifier>ISSN: 0264-410X</identifier><identifier>EISSN: 1873-2518</identifier><identifier>DOI: 10.1016/j.vaccine.2006.11.066</identifier><identifier>PMID: 17227690</identifier><identifier>CODEN: VACCDE</identifier><language>eng</language><publisher>Oxford: Elsevier</publisher><subject>Animals ; Applied microbiology ; Biological and medical sciences ; Biosafety ; Canarypox virus - genetics ; Dogs ; Drug Approval ; Fundamental and applied biological sciences. Psychology ; Genetic Vectors - genetics ; Hogs ; Horses ; Microbiology ; Miscellaneous ; Risk assessment ; Vaccines ; Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies (general aspects) ; Vaccines, Synthetic - adverse effects ; Vaccines, Synthetic - genetics ; Vaccines, Synthetic - therapeutic use ; Viral Vaccines - adverse effects ; Viral Vaccines - genetics ; Viral Vaccines - therapeutic use ; Virology</subject><ispartof>Vaccine, 2007-07, Vol.25 (30), p.5606-5612</ispartof><rights>2007 INIST-CNRS</rights><rights>Copyright Elsevier Limited Jul 26, 2007</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.proquest.com/docview/1559090081?pq-origsite=primo$$EHTML$$P50$$Gproquest$$H</linktohtml><link.rule.ids>309,310,314,778,782,787,788,23913,23914,25123,27907,27908,64366,64368,64370,72220</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=18958586$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/17227690$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>POULET, Hervé</creatorcontrib><creatorcontrib>MINKE, Jules</creatorcontrib><creatorcontrib>PARDO, Maria Camila</creatorcontrib><creatorcontrib>JUILLARD, Véronique</creatorcontrib><creatorcontrib>NORDGREN, Bob</creatorcontrib><creatorcontrib>AUDONNET, Jean-Christophe</creatorcontrib><title>Development and registration of recombinant veterinary vaccines The example of the canarypox vector platform</title><title>Vaccine</title><addtitle>Vaccine</addtitle><description>The canarypox vaccine vector (ALVAC) technology has been used to develop and license several vaccines for companion animals and horses in the European Union and USA. ALVAC is a ubiquitous vector with high biosafety since it is non-replicative in mammalians, is genetically and physically stable, and able to induce both humoral and cell-mediated immune responses against the expressed transgene product. Specific rules apply for the development and registration of recombinant vector vaccines. The biology of the vector as well as the recombinant virus must be thoroughly documented to allow the risk assessment of its use in the target species. In particular, its safety for the host and the environment must be extensively demonstrated before field trials can be authorized.</description><subject>Animals</subject><subject>Applied microbiology</subject><subject>Biological and medical sciences</subject><subject>Biosafety</subject><subject>Canarypox virus - genetics</subject><subject>Dogs</subject><subject>Drug Approval</subject><subject>Fundamental and applied biological sciences. Psychology</subject><subject>Genetic Vectors - genetics</subject><subject>Hogs</subject><subject>Horses</subject><subject>Microbiology</subject><subject>Miscellaneous</subject><subject>Risk assessment</subject><subject>Vaccines</subject><subject>Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies (general aspects)</subject><subject>Vaccines, Synthetic - adverse effects</subject><subject>Vaccines, Synthetic - genetics</subject><subject>Vaccines, Synthetic - therapeutic use</subject><subject>Viral Vaccines - adverse effects</subject><subject>Viral Vaccines - genetics</subject><subject>Viral Vaccines - therapeutic use</subject><subject>Virology</subject><issn>0264-410X</issn><issn>1873-2518</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2007</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>8G5</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNqF0M-L1TAQB_Agivt29U9QCqK31snv9Ci7ugoLXlbwVqbpVPtom5rkPdb_3jx8InjxlBnmkwn5MvaCQ8OBm7f75ojeTys1AsA0nDdgzCO2487KWmjuHrMdCKNqxeHrBbtMaQ8AWvL2KbvgVghrWtix-YaONIdtoTVXuA5VpG9TyhHzFNYqjKX3YemnFcv8SJliKePP6vx4qu6_U0UPuGwznXgurccT2cJDueBziNU2Yx5DXJ6xJyPOiZ6fzyv25cP7--uP9d3n20_X7-7qTbQu19Zo0WpElH0_WqU0Oen7oedKOoXCgO91zyUKIlJ20Kj4OHCBaIVy3rfyir35vXeL4ceBUu6WKXmaZ1wpHFJnwQrDJf8vFGChBCULfPUP3IdDXMsnOq51Cy2AO617eVaHfqGh2-K0lCS6P3EX8PoMMHmcx4irn9Jf51rttDPyFz77kpU</recordid><startdate>20070726</startdate><enddate>20070726</enddate><creator>POULET, Hervé</creator><creator>MINKE, Jules</creator><creator>PARDO, Maria Camila</creator><creator>JUILLARD, Véronique</creator><creator>NORDGREN, Bob</creator><creator>AUDONNET, Jean-Christophe</creator><general>Elsevier</general><general>Elsevier Limited</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>3V.</scope><scope>7QL</scope><scope>7RV</scope><scope>7T2</scope><scope>7T5</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88C</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AEUYN</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9-</scope><scope>K9.</scope><scope>KB0</scope><scope>LK8</scope><scope>M0R</scope><scope>M0S</scope><scope>M0T</scope><scope>M1P</scope><scope>M2O</scope><scope>M7N</scope><scope>M7P</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>Q9U</scope><scope>7QO</scope><scope>8FD</scope><scope>FR3</scope><scope>P64</scope><scope>7X8</scope></search><sort><creationdate>20070726</creationdate><title>Development and registration of recombinant veterinary vaccines The example of the canarypox vector platform</title><author>POULET, Hervé ; MINKE, Jules ; PARDO, Maria Camila ; JUILLARD, Véronique ; NORDGREN, Bob ; AUDONNET, Jean-Christophe</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p298t-765295aaa3bbf7445e83cbdb14384a260cb5b13a2eee47d5a41fd12aa7248cc93</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2007</creationdate><topic>Animals</topic><topic>Applied microbiology</topic><topic>Biological and medical sciences</topic><topic>Biosafety</topic><topic>Canarypox virus - genetics</topic><topic>Dogs</topic><topic>Drug Approval</topic><topic>Fundamental and applied biological sciences. Psychology</topic><topic>Genetic Vectors - genetics</topic><topic>Hogs</topic><topic>Horses</topic><topic>Microbiology</topic><topic>Miscellaneous</topic><topic>Risk assessment</topic><topic>Vaccines</topic><topic>Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies (general aspects)</topic><topic>Vaccines, Synthetic - adverse effects</topic><topic>Vaccines, Synthetic - genetics</topic><topic>Vaccines, Synthetic - therapeutic use</topic><topic>Viral Vaccines - adverse effects</topic><topic>Viral Vaccines - genetics</topic><topic>Viral Vaccines - therapeutic use</topic><topic>Virology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>POULET, Hervé</creatorcontrib><creatorcontrib>MINKE, Jules</creatorcontrib><creatorcontrib>PARDO, Maria Camila</creatorcontrib><creatorcontrib>JUILLARD, Véronique</creatorcontrib><creatorcontrib>NORDGREN, Bob</creatorcontrib><creatorcontrib>AUDONNET, Jean-Christophe</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>ProQuest Central (Corporate)</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Nursing & Allied Health Database</collection><collection>Health and Safety Science Abstracts (Full archive)</collection><collection>Immunology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Healthcare Administration Database (Alumni)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest One Sustainability</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection (ProQuest)</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>ProQuest Biological Science Collection</collection><collection>Consumer Health Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Healthcare Administration Database</collection><collection>Medical Database</collection><collection>Research Library</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central Basic</collection><collection>Biotechnology Research Abstracts</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Vaccine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>POULET, Hervé</au><au>MINKE, Jules</au><au>PARDO, Maria Camila</au><au>JUILLARD, Véronique</au><au>NORDGREN, Bob</au><au>AUDONNET, Jean-Christophe</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Development and registration of recombinant veterinary vaccines The example of the canarypox vector platform</atitle><jtitle>Vaccine</jtitle><addtitle>Vaccine</addtitle><date>2007-07-26</date><risdate>2007</risdate><volume>25</volume><issue>30</issue><spage>5606</spage><epage>5612</epage><pages>5606-5612</pages><issn>0264-410X</issn><eissn>1873-2518</eissn><coden>VACCDE</coden><abstract>The canarypox vaccine vector (ALVAC) technology has been used to develop and license several vaccines for companion animals and horses in the European Union and USA. ALVAC is a ubiquitous vector with high biosafety since it is non-replicative in mammalians, is genetically and physically stable, and able to induce both humoral and cell-mediated immune responses against the expressed transgene product. Specific rules apply for the development and registration of recombinant vector vaccines. The biology of the vector as well as the recombinant virus must be thoroughly documented to allow the risk assessment of its use in the target species. In particular, its safety for the host and the environment must be extensively demonstrated before field trials can be authorized.</abstract><cop>Oxford</cop><pub>Elsevier</pub><pmid>17227690</pmid><doi>10.1016/j.vaccine.2006.11.066</doi><tpages>7</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0264-410X |
| ispartof | Vaccine, 2007-07, Vol.25 (30), p.5606-5612 |
| issn | 0264-410X 1873-2518 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_70726131 |
| source | Elsevier ScienceDirect Journals Complete - AutoHoldings; MEDLINE; ProQuest Central UK/Ireland |
| subjects | Animals Applied microbiology Biological and medical sciences Biosafety Canarypox virus - genetics Dogs Drug Approval Fundamental and applied biological sciences. Psychology Genetic Vectors - genetics Hogs Horses Microbiology Miscellaneous Risk assessment Vaccines Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies (general aspects) Vaccines, Synthetic - adverse effects Vaccines, Synthetic - genetics Vaccines, Synthetic - therapeutic use Viral Vaccines - adverse effects Viral Vaccines - genetics Viral Vaccines - therapeutic use Virology |
| title | Development and registration of recombinant veterinary vaccines The example of the canarypox vector platform |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-16T10%3A55%3A19IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Development%20and%20registration%20of%20recombinant%20veterinary%20vaccines%20The%20example%20of%20the%20canarypox%20vector%20platform&rft.jtitle=Vaccine&rft.au=POULET,%20Herv%C3%A9&rft.date=2007-07-26&rft.volume=25&rft.issue=30&rft.spage=5606&rft.epage=5612&rft.pages=5606-5612&rft.issn=0264-410X&rft.eissn=1873-2518&rft.coden=VACCDE&rft_id=info:doi/10.1016/j.vaccine.2006.11.066&rft_dat=%3Cproquest_pubme%3E3420807511%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1559090081&rft_id=info:pmid/17227690&rfr_iscdi=true |